# EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma

> **NCT02664363** · PHASE1 · TERMINATED · sponsor: **Daniel Landi** · enrollment: 3 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma

## Interventions

- **BIOLOGICAL:** EGFRvIII CAR T cells

## Key facts

- **NCT ID:** NCT02664363
- **Lead sponsor:** Daniel Landi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-01
- **Primary completion:** 2018-09-25
- **Final completion:** 2019-09-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study funding ended
- **Last updated:** 2023-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02664363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02664363, "EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02664363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*